Roberta Ballard

  1. Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant.
  2. Composition and origin of lung fluid proteome in premature infants and relationship to respiratory outcome.
  3. Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE).
  4. Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants.
  5. Surfactant status and respiratory outcome in premature infants receiving late surfactant treatment.
  6. Reply.
  7. Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial.
  8. Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis.
  9. Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development.
  10. Reply.
  11. The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age.
  12. Characteristics of Extremely Low Gestational Age Newborns Undergoing Tracheotomy: A Secondary Analysis of the Trial of Late Surfactant Randomized Clinical Trial.
  13. Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns.
  14. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial.
  15. Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials.
  16. Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program.
  17. Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide.
  18. Prematurity and respiratory outcomes program (PROP): study protocol of a prospective multicenter study of respiratory outcomes of preterm infants in the United States.
  19. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach.
  20. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy.
  21. Inhaled nitric oxide increases urinary nitric oxide metabolites and cyclic guanosine monophosphate in premature infants: relationship to pulmonary outcome.
  22. Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study.
  23. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics.
  24. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials.
  25. Pilot trial of late booster doses of surfactant for ventilated premature infants.
  26. Re: 'The use of iNO in the newborn period: results from the European iNO registry'.
  27. Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis.
  28. Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide.
  29. Accounting for multiple births in neonatal and perinatal trials: systematic review and case study.
  30. Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
  31. Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites.
  32. Expression of nitric oxide synthases and endogenous NO metabolism in bronchopulmonary dysplasia.
  33. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial.
  34. Inhaled nitric oxide for preterm infants.
  35. Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants.
  36. Therapeutic hypothermia changes the prognostic value of clinical evaluation of neonatal encephalopathy.
  37. Inhaled nitric oxide in preterm infants--correction.
  38. The effect of inhaled nitric oxide on pulmonary function in preterm infants.
  39. Surfactant function and composition in premature infants treated with inhaled nitric oxide.
  40. Determinants of outcomes after head cooling for neonatal encephalopathy.
  41. Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide.
  42. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
  43. Urinary metabolites of oxidative stress and nitric oxide in preterm and term infants.
  44. Neonatal - perinatal medicine fellowship training in long-term outcomes of neonatal intensive care unit graduates.
  45. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial.
  46. Dysfunction of pulmonary surfactant in chronically ventilated premature infants.
  47. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease.
  48. Surfactant protein profile of pulmonary surfactant in premature infants.
  49. Plasma 3-nitrotyrosine and outcome in neonates with severe bronchopulmonary dysplasia after inhaled nitric oxide.
  50. Pulmonary surfactant for neonatal respiratory disorders.
  51. Interaction of endogenous endothelin-1 and inhaled nitric oxide in term and preterm infants.
  52. Fear of litigation may increase resuscitation of infants born near the limits of viability.
  53. Multiple courses of antenatal corticosteroids are associated with early severe lung disease in preterm neonates.
  54. Association of plasma cortisol and chronic lung disease in preterm infants.
  55. Clinical use of antenatal corticosteroids: benefits and risks.
  56. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group.
  57. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia.
  58. Antenatal hormone therapy for fetal lung maturation.
  59. Plasma thyroid hormones in premature infants: effect of gestational age and antenatal thyrotropin-releasing hormone treatment. TRH Collaborative Trial Participants.
  60. Plasma 3-nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia.
  61. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin-Releasing Hormone Study Group.
  62. Antenatal hormone therapy for improving the outcome of the preterm infant.
  63. Partial deficiency of surfactant protein B in an infant with chronic lung disease.
  64. Thyrotropin-releasing hormone for prevention of neonatal respiratory disease.
  65. Outcome of very low birth weight infants: multiple gestation versus singletons.
  66. Plasma thyroid hormones and prolactin in premature infants and their mothers after prenatal treatment with thyrotropin-releasing hormone.
  67. Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid. TRH Study Group.
  68. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease.
  69. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study.
  70. Effect of medical and social risk factors on outcome of prematurity and very low birth weight.
  71. Theophylline treatment in the extubation of infants weighing less than 1,250 grams: a controlled trial.
  72. Developmental follow-up of infants with persistent pulmonary hypertension of the newborn.
  73. Risk factor analysis of intraventricular hemorrhage in low-birth-weight infants.
  74. Prenatal administration of betamethasone for prevention of patient ductus arteriosus.
  75. Fetal sex and prenatal betamethasone therapy.
  76. Glucocorticoids in prevention of respiratory distress syndrome.
  77. Control of oxygenation during the transport of sick neonates.
  78. Preliminary observations on the behavior of children present at the birth of a sibling.
  79. Nosocomial respiratory syncytial virus infections in an intensive care nursery: rapid diagnosis by direct immunofluorescence.
  80. Acquired cytomegalovirus infection in preterm infants.
  81. What pediatricians say to mothers of sick newborns: an indirect evaluation of the counseling process.
  82. Corticosteroids and respiratory distress syndrome: status 1979.
  83. Prenatal administration of betamethasone for prevention of respiratory distress syndrome.
  84. Use of prenatal glucocorticoid therapy to prevent respiratory distress syndrome. A supporting view.
  85. Hydrocephalus secondary to intracranial hemorrhage in premature infants.
  86. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome.
  87. Cytoplasmic receptor for glucocorticoids in lung of the human fetus and neonate.
  88. Idiopathic respiratory distress syndrome. Treatment with continuous negative-pressure ventilation.